KOE · 215600.KQ
SillaJen, Inc.
₩2,020-₩40 (-1.94%)
SillaJen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.59% below the high.
Loading market information…
KOE · 095700.KQ · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 05:22 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Genexine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.09% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Genexine, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Genexine, Inc. is a South Korean clinical-stage biotechnology firm dedicated to advancing and commercializing immunotherapeutics and extended-duration biologics. The company leverages two key proprietary technologies: the hyFc platform, engineered for discovering diverse agonistic protein therapeutics, and an Immune Enhancing Technology, which focuses on therapeutic DNA vaccines. Its extensive pipeline features several drug candidates: GX-H9, currently in Phase II trials for treating growth hormone deficiency in both adults and children; GX-E2, also in Phase II, addressing induced anemia; GX-G3, in Phase II for neutropenia; and GX-G6, undergoing Phase I studies for diabetes. Additionally, GX-188E is in Phase II clinical trials, being evaluated in combination with KEYTRUDA for cervical cancer treatment. Genexine has also forged a co-development alliance with Binex Co. Ltd. to create a COVID-19 vaccine. Founded in 1999 as Genexine Co., Ltd., the company adopted its current name, Genexine, Inc., in March 2013 and is headquartered in Seongnam, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -₩589 |
| ₩305.84M |
| Q3 2024 | Nov 14, 2024 | -₩351 | ₩209.18M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩2,020-₩40 (-1.94%)
SillaJen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.59% below the high.
₩2,505-₩55 (-2.15%)
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.78% below the high.
₩5,810-₩110 (-1.86%)
JETEMA, Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.49% below the high.
₩5,250-₩100 (-1.87%)
EASY BIO,Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.67% below the high.
₩3,680+₩60 (+1.66%)
Helixmith Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 63.05% below the high.
₩13,420-₩660 (-4.69%)
Anterogen.Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
₩10,860-₩90 (-0.82%)
Macrogen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.04% below the high.
₩915+₩9 (+0.99%)
Amicogen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.8% below the high.
